<table>
<thead>
<tr>
<th>タイトル</th>
<th>Predominant Infiltration of Monocytes in Chronic Graft-Versus-Host Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>著者</td>
<td>Namba, Noriko / Shinagawa, Katsuji / Fujii, Nobuharu / Maeda, Yoshinobu / Ishimaru, Fumihiko / Ikeda, Kazuma / Matsui, Toshimitsu / Tanimoto, Mitsune / Katayama, Yoshio</td>
</tr>
<tr>
<td>掲載誌・巻号・ページ</td>
<td>Transplantation, 83(2):220-224</td>
</tr>
<tr>
<td>刊行日</td>
<td>2007-01-27</td>
</tr>
<tr>
<td>資源タイプ</td>
<td>Journal Article / 学術雑誌論文</td>
</tr>
<tr>
<td>版区分</td>
<td>author</td>
</tr>
<tr>
<td>権利</td>
<td>This is a non-final version of an article published in final form in Transplantation: 27 January 2007 - Volume 83 - Issue 2 - pp 220-224</td>
</tr>
<tr>
<td>DOI</td>
<td>10.1097/01.tp.0000245080.71722.87</td>
</tr>
<tr>
<td>JaLCDOI</td>
<td></td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://www.lib.kobe-u.ac.jp/handle_kernel/90000765">http://www.lib.kobe-u.ac.jp/handle_kernel/90000765</a></td>
</tr>
</tbody>
</table>

PDF issue: 2018-12-11
Brief report

Predominant infiltration of monocytes in chronic graft-versus-host disease

Noriko Namba 1, Katsuji Shinagawa 1, Nobuharu Fujii 1, Yoshinobu Maeda 1, Fumihiko Ishimaru 1, Kazuma Ikeda 1, Toshimitsu Matsui 2, Mitsune Tanimoto 1 and Yoshio Katayama 2*

From the 1Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 700-8558; 2Hematology/Oncology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan

Keywords: fractalkine, CX3CR1, monocyte, chronic GVHD

Word count: abstract 150, text 1280

Figures/Tables: 2 figures (1 color figure),

Online supplemental materials: 1 supplemental methods (text), 2 supplemental figures, and 2 supplemental tables

* Correspondence to: Yoshio Katayama, MD, PhD
Hematology/Oncology, Department of Medicine,
Kobe University Graduate School of Medicine,
7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
phone: +81-78-382-5885
fax: +81-78-382-5899
e-mail: katayama@med.kobe-u.ac.jp
Footnotes

Grants: This work was supported in part by The Okayama Medical Foundation and Ryobi Teien Memory Foundation to Y.K.

Authors have no conflict of interest regarding this work.

1. Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan

2. Hematology/Oncology, Department of Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

* Correspondence to:
Yoshio Katayama, MD, PhD
Hematology/Oncology, Department of Medicine,
Kobe University Graduate School of Medicine,
7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
phone: +81-78-382-5885
fax: +81-78-382-5899
e-mail: katayama@med.kobe-u.ac.jp
Abstract

Pathogenesis of chronic graft versus host disease (cGVHD) is largely unknown. It is important to determine the responsible cell types and the factors that play roles to recruit these cells into sites of disease. We examined whether monocytes and chemokine fractalkine/receptor CX3CR1 axis might be involved. We found that the absolute number of CX3CR1+ monocytes in the blood was significantly decreased in patients with severe cGVHD. Immunohistochemical staining revealed the extensive infiltration of CD14+ cells as well as strong expression of fractalkine in the cGVHD skin. The number of infiltrated CD14+ cells on the margin of fractalkine+ epidermis was larger in cGVHD skin compared to that of acute GVHD, whereas no difference was observed in CD3+ T cells. These results suggest that CX3CR1+ monocytes may be recruited from the circulation to the fractalkine+ epidermis in cGVHD, and highlight these cells and this chemokine/receptor axis as additional targets for cGVHD therapy.

(word count 150)
Introduction

Chronic graft versus host disease (cGVHD) is the most common late complication of allogeneic stem cell transplantation (alloSCT) (1). Clinical management of cGVHD depends on immunosuppressive agents to target lymphocytes, but therapy is complicated by untoward side effects, infections and frequent failure to control the underlying process. More than 20% of primary causes of death is cGVHD among patients who are disease free two years after alloSCT (2). To establish a better therapeutic strategy, it is important to determine the cell types and the mediators that are responsible for cGVHD.

The role of chemokines in acute GVHD (aGVHD) has been actively studied (3). However, few reports have examined their role in cGVHD (4-6). Fractalkine/CX3CL1 is an unique chemokine that exists not only as a chemo-attracting soluble factor but also as a membrane-anchored form that mediates adhesion of leukocytes expressing its cognitive receptor CX3CR1 to the endothelium (7, 8). Monocyte is one of the major cell types which express CX3CR1 (8, 9). The immune responses of fractalkine-deficient mice to a variety of T cell-mediated inflammatory stimuli, such as delayed-type hypersensitivity, were not impaired (10). However, fractalkine- or CX3CR1-deficient mice exhibited reduced atherogenesis due to impaired recruitment of monocytes (11, 12). The strong expression of fractalkine or predominant infiltration of monocytes has been reported in some chronic autoimmune disorders.
Because autoimmune disorders and cGVHD share many clinical manifestations, we focused on monocytes as a candidate of responsible cell type other than lymphocytes. We examined their distribution in the blood and skin of cGVHD patients in association with chemokine fractalkine/receptor CX3CR1 axis.

Materials and Methods

Blood and tissue samples

Peripheral blood samples for flow cytometric analyses were obtained from 19 patients who had undergone alloSCT (11 men, 8 women; age: range 20-71, median 41; days after transplantation: range 97-3523, median 681, conditioning: 11 received myeloablative, 8 non-myeloablative regimen, 8 containing total body irradiation (TBI), stem cell source: 11 related peripheral blood stem cell, 5 unrelated bone marrow, 2 related bone marrow, 1 cord blood. The profile of each patient is listed in Supplemental Table 1). Skin biopsy specimens were obtained from alloSCT patients (7 with active rash due to aGVHD, 7 with active rash due to cGVHD and 7 without skin cGVHD. Each group consists of 4 patients who received myeloablative transplantation with TBI and 3 non-myeloablative transplantation with fludarabine containing regimen. The profile of each patient is listed in Supplemental Table 2). All patients studied had no evidence of infection. The protocol was approved by the Institutional Review Board of
Okayama University and informed consent was obtained from patients.

Clinical assessment

The clinical severity of cGVHD was assessed according to the report of National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in cGVHD (16). The sum of the each score was used as cGVHD score. The severity of cGVHD was categorized in cGVHD(−)-mild, moderate and severe groups as described (16).

Flow cytometry, Immunohistochemistry, Statistics

Methods can be found in supplemental online materials.
Results and Discussion

CX3CR1+ monocytes were decreased in the blood of severe cGVHD patients

As shown in Figure 1A, CD14+ monocytes in patients with no cGVHD symptom displayed high CX3CR1 expression level (range: 52-83%). Non-transplanted normal individuals showed similar level of expression (not shown). We noticed that this expression was low in patients with severe cGVHD (Figure 1A). Correlation between percentage of CX3CR1 positive cells in CD14+ fraction and cGVHD severity score is shown in Figure 1B. There was a strong inverse correlation between cGVHD score and CX3CR1 expression (n=19, p<0.01). Although the numbers of monocytes in the blood were similar in each category (Figure 1C), the absolute number of CX3CR1 positive monocytes was drastically decreased in patients with severe cGVHD (Figure 1D). Although it is still possible that some minor lymphocyte subsets might show a correlation similar to that observed in monocytes, the analysis of total lymphocytes characterized by low forward and side scatter from same 19 samples did not display such a trend (Supplemental Figure 1). These data suggest that the reduction of CX3CR1 positive cells in severe cGVHD patients may be specific for monocytes.

Fractalkine expression and monocyte infiltration in GVHD skin tissues

We first examined skin tissues at the sites of normal appearance, pigmentation and active rash from a patient with skin cGVHD (Figure 2A). Fractalkine was faintly
expressed in epidermis at the sites of normal appearance and pigmentation (Figure 2B) similar to that in skin from non-transplanted healthy donor (not shown). In contrast, it was strongly expressed in epidermis with hyperplasia in the skin with active rash (Figure 2B). Very few CD14+ cells were observed at the sites of normal appearance and pigmentation (Figure 2B) as well as in the skin from non-transplanted healthy donor (not shown). In sharp contrast, dramatic infiltration of CD14+ cells was observed within the superficial dermis in active rash (Figure 2B). We observed strong epidermal fractalkine expression in all cGVHD samples with some variety of its level. The number of infiltrated CD14+ cells was significantly higher in skin with rash compared to those with normal appearance from transplanted patients (Figure 2C, n=7, p<0.01). These data suggest that the strong expression of fractalkine and the infiltration of CD14+ cells are not due to the preparative regimen for alloSCT but likely specific phenomenon in active skin cGVHD.

Epidermal fractalkine expression was also observed in aGVHD skin, with a wide variety in its level (from no to relatively strong expression). Remarkably, the fractalkine positive area was greatly wider in cGVHD (Supplemental Figure 2), which is consistent with the feature that aGVHD does not show epidermal hyperplasia (17). Epidermal hyperplasia is due to the hyperproliferation of keratinocytes, known as a main fractalkine producer in the skin (15). The total amount of fractalkine production from epidermis in cGVHD skin may be much higher than that in aGVHD.
During the study of CD14+ cells in cGVHD skin tissues, we noticed that the infiltration of CD14+ cells was strongly observed at the site along the edge of the dermis bordering the epidermis (Figure 2D), as if these cells were attracted to the epidermis. The number of CD3+ T cells in this specific area showed no difference between acute and chronic GVHD (Figure 2E). Interestingly, there was a trend toward higher number of total cells in cGVHD, and the number of CD14+ cells in cGVHD was significantly higher than that in aGVHD skin in this bordering area (Figure 2E). These results suggest that, in comparison with aGVHD, cGVHD skin is characterized by the strong expression of epidermal fractalkine accompanied by the extensive infiltration of CD14+ cells near this area. However, this may not necessarily apply to all cGVHD patients because cGVHD affects various organs and clinical presentation of skin lesions varies.

It has been reported that, among CD14+ monocytes, CX3CR1\textsuperscript{high} cells are preferentially attracted by fractalkine compared to other monocytes and that these cells are the precursor of antigen presenting cells (APCs) (9). Shlomchik et al. have reported that, in contrast to acute GVHD which requires host APCs, donor APCs are required to initiate cGVHD in their mouse model (18). It would be important to determine whether the CD14+ cells in the skin are definitely monocytes or could be APCs such as dendritic cells, and whether these cells are host or donor origin.

In conclusion, our data suggest the potential involvement of monocytes in
cGVHD via the fractalkine-CX3CR1 pathway, and highlight these previously unappreciated cells and chemokine-receptor axis as additional targets for cGVHD therapy.

Acknowledgments

We thank Drs. Ichiro Yamadori (Department of Laboratory Medicine, National Okayama Medical Center), Shinichi Toyooka (Department of Cancer and Thoracic Surgery, Okayama University Hospital), Gen Nakanishi (Department of Dermatology, Okayama University Hospital) for the tissue samples.
References


Figure legends

Figure 1. CX3CR1 positive monocyte in the blood is decreased in patients with severe cGVHD. (A) Representative histograms of CX3CR1 expression in CD14+ fraction are shown. Gray: isotype matched control. (B) CX3CR1 expression level inversely correlates with severity of clinical symptoms in cGVHD patients. Spearman’s rank correlation coefficient, n=19, p<0.01, R=-0.73. (C) The numbers of peripheral blood total monocytes and (D) CX3CR1 positive monocytes. n=8 for cGVHD(-)-mild, 5 for moderate, and 6 for severe group. *p<0.05, **p<0.01.

Figure 2. Immunohistochemical staining of fractalkine and CD14 in GVHD skin tissues. (A) A picture of a patient with active cGVHD skin rash. (B) Fractalkine and CD14 staining in skin samples from this patient as indicated in (A). Violet color shows positive staining of target antigens visualized by VIP. Methyelgreen was used for the counterstain. No non-specific staining with control antibody was observed in all experiments. Bar: 200 μm. (C) The number of infiltrated CD14 positive cells in skin tissues from transplanted patients with or without skin cGVHD. Box-and whisker plots. n=7 for each group. **p<0.01. (D) A representative picture of CD3 (visualized by DAB, brown)/CD14 (VIP, violet) dual color staining of cGVHD skin. Red dotted line indicates the margin of epidermis (200μm). (E) The number of cells located on the
margin of epidermis in acute and chronic GVHD skin tissues (/ 1 mm). Box-and
whisker plots. n=7 for each group. *p<0.05.
Figure 1

(A) 

(B) 

(C) 

(D) 

(A) 

(B) 

(C) 

(D)
Figure 2

(A) 

(B) 

fractalkine

CD14

(C) 

Normal appearance
Skin rash (+)

# of infiltrated CD14+ cells

(D) 

(E) 

Total cells
CD3+ cells
CD14+ cells

acute chronic
acute chronic
acute chronic

* **
Supplemental Materials

Supplemental Methods

Flow cytometry

Blood samples were stained with PE-conjugated anti-human CD14 antibody (CALTAG, Burlingame, CA) together with FITC-conjugated anti-human CX3CR1 antibody (MBL, Nagoya, Japan) or FITC-conjugated isotype-matched control (MBL), followed by the lysis of red blood cells with lysing solution (BD Pharmingen, San Jose, CA). Analysis was performed on a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA).

Immunohistochemistry

Formalin-fixed and paraffin-embedded specimens were sliced at 5 μm thickness and deparaffinized followed by antigen retrieval with microwave in citrate buffer. Samples were dipped in 3% H₂O₂ to quench endogenous peroxidase, then blocked with phosphate-buffered saline (PBS)+5% horse serum, incubated with polyclonal goat anti-human Fractalkine antibody (R&D systems, Minneapolis, MN) or control goat IgG (Sigma, St. Louis, MO), followed by the incubation with biotinylated horse anti-goat IgG (Vector Laboratories, Burlingame, CA). Avidin-biotin-peroxidase complex (ABC) kit (Vector Laboratories) was used to enhance the staining signals.
Antigens were visualized by VIP (Vector Laboratories). For CD14 staining, samples were blocked with PBS+5% sheep serum, incubated with biotinylated sheep anti-human CD14 antibody (R&D systems) or control biotinylated sheep IgG (Vector Laboratories). ABC kit (Vector Laboratories) and VIP (Vector Laboratories) were used to visualize the staining. For dual color staining with CD3, samples were then washed twice in PBS, blocked with PBS+5% horse serum, and incubated with mouse anti-human CD3 antibody (Novocastra, Newcastle upon Tyne, UK) or control mouse IgG (Sigma) followed by biotinylated-horse anti-mouse IgG (Vector Laboratories). ABC kit (Vector Laboratories) and DAB (Vector Laboratories) were used to visualize the staining. Methylgreen (Vector Laboratories) was used for the counterstain. Stainings with control antibodies were performed in all experiments and showed no significant non-specific staining (not shown). The number of infiltrated CD14+ cells in cGVHD and transplanted normal skin tissues was counted in randomly selected three rectangles (200 x 400 μm) in dermis near epidermis, and was represented by the average (Figure 2C). For the comparison between acute and chronic GVHD, both CD14+ and CD3+ cells in dual color stained-skin tissues were counted on the edge of the dermis bordering the epidermis (Figure 2D, red dotted line).

Statistics

Spearman’s rank correlation coefficient was used to determine the correlations
Mann-Whitney’s U-test was used for non-parametric comparison. P<0.05 was considered statistically significant.

**Supplemental Figure legends**

Supplemental Figure 1. CX3CR1 expression on peripheral blood lymphocytes in cGVHD patients. (A) Representative histograms of CX3CR1 expression in lymphocyte fraction (low forward and side scatter) are shown. Gray: isotype control. (B) CX3CR1 expression level shows no correlation with severity of clinical symptoms in cGVHD patients (Spearman’s rank correlation coefficient). NS: not significant. (C) The numbers of peripheral blood total lymphocytes and (D) CX3CR1 positive lymphocytes. n=8 for cGVHD(-)-mild, 5 for moderate, and 6 for severe group.

Supplemental Figure 2. Immunohistochemical staining of fractalkine (VIP, violet) in (A) acute and (B) chronic GVHD skin tissues. Red dotted line: the width of epidermis. Black bar: 100μm.
Supplemental Figure 1

(A) 

(B) NS

(C) 

(D)
Supplemental Figure 2
Supplemental Table 1. Patient profile (blood sampling)

<table>
<thead>
<tr>
<th>Grade</th>
<th>cGVHD score</th>
<th>Sex</th>
<th>Age</th>
<th>Disease</th>
<th>Stem cell source</th>
<th>Conditioning</th>
<th>Day after transplantation</th>
<th>Immunosuppressant/day</th>
<th>cGVHD status</th>
<th>Duration of cGVHD/day</th>
<th>% CX3CR1+ in CD14+ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>mild</td>
<td>1</td>
<td>M/F</td>
<td>35</td>
<td>AML</td>
<td>R-PBSC</td>
<td>AraC + TBI</td>
<td>855</td>
<td>FK506 0.5/1mg alternative</td>
<td>stable 300</td>
<td>69</td>
<td>71</td>
</tr>
<tr>
<td>mild</td>
<td>1</td>
<td>M/F</td>
<td>20</td>
<td>AML</td>
<td>R-PBSC</td>
<td>Flu + CY</td>
<td>47</td>
<td>FK506 2.5mg</td>
<td>onset 0</td>
<td>40</td>
<td>60</td>
</tr>
<tr>
<td>mild</td>
<td>1</td>
<td>M/F</td>
<td>61</td>
<td>CML</td>
<td>R-PBSC</td>
<td>Flu + CY</td>
<td>52</td>
<td>FK506 0.5/1mg alternative</td>
<td>stable 300</td>
<td>60</td>
<td>52</td>
</tr>
<tr>
<td>mild</td>
<td>3</td>
<td>M/M</td>
<td>30</td>
<td>NHL</td>
<td>R-PBSC</td>
<td>AraC + TBI</td>
<td>3523</td>
<td>PSL 5mg/2 days</td>
<td>stable 2947</td>
<td>51</td>
<td>71</td>
</tr>
<tr>
<td>moderate</td>
<td>4</td>
<td>F/M</td>
<td>40</td>
<td>NHL</td>
<td>R-PBSC</td>
<td>Flu + CY</td>
<td>337</td>
<td>PSL 10mg, FK506 2mg</td>
<td>stable 238</td>
<td>41</td>
<td>41</td>
</tr>
<tr>
<td>moderate</td>
<td>4</td>
<td>M/F</td>
<td>71</td>
<td>NHL</td>
<td>R-PBSC</td>
<td>Flu + CY+Rit</td>
<td>1531</td>
<td>CsA 25mg (twice/week)</td>
<td>stable 973</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>moderate</td>
<td>4</td>
<td>M/F</td>
<td>55</td>
<td>MDS</td>
<td>R-PBSC</td>
<td>Flu + CY</td>
<td>231</td>
<td>CsA 250mg</td>
<td>worsening 7</td>
<td>69</td>
<td>69</td>
</tr>
<tr>
<td>moderate</td>
<td>4</td>
<td>M/F</td>
<td>64</td>
<td>NHL</td>
<td>R-PBSC</td>
<td>Flu + BU</td>
<td>308</td>
<td>CsA 100mg, PSL 5mg</td>
<td>onset 0</td>
<td>60</td>
<td>60</td>
</tr>
<tr>
<td>moderate</td>
<td>4</td>
<td>M/F</td>
<td>45</td>
<td>MM</td>
<td>R-PBSC</td>
<td>Flu + L-PAM</td>
<td>314</td>
<td>CsA 100mg, PSL 20mg</td>
<td>stable 151</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>severe</td>
<td>5</td>
<td>F/F</td>
<td>50</td>
<td>CML</td>
<td>R-PBSC</td>
<td>Flu + CY</td>
<td>1747</td>
<td>CsA 25mg, PSL 20mg</td>
<td>stable 1357</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>severe</td>
<td>6</td>
<td>F/M</td>
<td>29</td>
<td>ALL</td>
<td>R-PBSC</td>
<td>Flu + TBI</td>
<td>706</td>
<td>CsA 150mg, PSL 50mg</td>
<td>stable 147</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>severe</td>
<td>6</td>
<td>M/F</td>
<td>34</td>
<td>ALL</td>
<td>R-PBSC</td>
<td>Flu + TBI</td>
<td>681</td>
<td>CsA 100mg</td>
<td>stable 39</td>
<td>52</td>
<td>52</td>
</tr>
<tr>
<td>severe</td>
<td>9</td>
<td>M/F</td>
<td>37</td>
<td>CML</td>
<td>R-BM</td>
<td>Flu + CY</td>
<td>2786</td>
<td>PSL 15mg, FK506 4mg</td>
<td>stable 2786</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>severe</td>
<td>9</td>
<td>M/M</td>
<td>31</td>
<td>NHL</td>
<td>R-BM</td>
<td>Flu + CY</td>
<td>142</td>
<td>CsA 50mg, PSL 5mg</td>
<td>stable 30</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>severe</td>
<td>11</td>
<td>F/F</td>
<td>33</td>
<td>AML</td>
<td>R-PBSC</td>
<td>Flu + TBI</td>
<td>692</td>
<td>PSL 15mg</td>
<td>stable 907</td>
<td>27</td>
<td>27</td>
</tr>
<tr>
<td>Condition</td>
<td>Sex</td>
<td>Age</td>
<td>Disease</td>
<td>Stem cell source</td>
<td>Day after transplantation</td>
<td>Immunosuppressant /day</td>
<td>Conditioning</td>
<td>Skin type</td>
<td>Site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>--------</td>
<td>-----</td>
<td>---------</td>
<td>------------------</td>
<td>--------------------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cGVHD</td>
<td>M/M</td>
<td>54</td>
<td>AML</td>
<td>UR-BM</td>
<td>615</td>
<td>FK506 2mg</td>
<td>CY/TBI</td>
<td>erythematous plaque</td>
<td>face</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F/F</td>
<td>17</td>
<td>ALL</td>
<td>R-BM</td>
<td>391</td>
<td>FK506 4.5mg/ day</td>
<td>L-PAM/Thiotepa/CY/TBI</td>
<td>sclerotic</td>
<td>dorsal hand</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F/F</td>
<td>44</td>
<td>ALL</td>
<td>R-PBSC</td>
<td>1133</td>
<td>CsA 100mg/PSL 5mg</td>
<td>L-PAM/TBI</td>
<td>lichenoid change</td>
<td>arm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>34</td>
<td>ALL</td>
<td>R-PBSC</td>
<td>768</td>
<td>CsA 100mg</td>
<td>CY/TBI</td>
<td>lichenoid change</td>
<td>palm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>49</td>
<td>MM</td>
<td>R-PBSC</td>
<td>559</td>
<td>CsA 100mg/PSL 20mg</td>
<td>Flu/L-PAM</td>
<td>psoriasiform</td>
<td>arm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>55</td>
<td>MDS</td>
<td>R-PBSC</td>
<td>287</td>
<td>CsA 250mg</td>
<td>Flu/CY</td>
<td>lichenoid change</td>
<td>face</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>57</td>
<td>NHL</td>
<td>UR-BM</td>
<td>574</td>
<td>CsA 100mg/PSL 5mg</td>
<td>Flu/BU</td>
<td>erythema</td>
<td>neck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>M/M</td>
<td>20</td>
<td>AML</td>
<td>UR-BM</td>
<td>393</td>
<td>-</td>
<td>CY/TBI</td>
<td>no eruption</td>
<td>back</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>38</td>
<td>CML</td>
<td>R-PBSC</td>
<td>953</td>
<td>PSL 25mg</td>
<td>CY/TBI</td>
<td>no eruption</td>
<td>arm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/M</td>
<td>47</td>
<td>CML</td>
<td>R-PBSC</td>
<td>1117</td>
<td>FK506 2mg/PSL 5-10mg</td>
<td>AraC/CY/TBI</td>
<td>no eruption</td>
<td>arm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>39</td>
<td>NHL</td>
<td>R-BM</td>
<td>335</td>
<td>CsA 100m/PSL 20mg</td>
<td>L-PAM/TBI</td>
<td>no eruption</td>
<td>abdomen</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>45</td>
<td>MM</td>
<td>R-PBSC</td>
<td>559</td>
<td>CsA 100mg/PSL 20mg</td>
<td>Flu/L-PAM</td>
<td>no eruption</td>
<td>arm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>55</td>
<td>MDS</td>
<td>R-PBSC</td>
<td>287</td>
<td>CsA 250mg</td>
<td>Flu/CY</td>
<td>no eruption</td>
<td>back</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>64</td>
<td>NHL</td>
<td>UR-BM</td>
<td>574</td>
<td>CsA 100mg/PSL 5mg</td>
<td>Flu/BU</td>
<td>no eruption</td>
<td>back</td>
<td></td>
<td></td>
</tr>
<tr>
<td>aGVHD</td>
<td>M/F</td>
<td>20</td>
<td>ALL</td>
<td>UR-BM</td>
<td>37</td>
<td>CsA 3mg/kg~., iv</td>
<td>CY/TBI</td>
<td>erythema</td>
<td>dorsal hand</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F/M</td>
<td>38</td>
<td>NHL</td>
<td>UR-BM</td>
<td>53</td>
<td>FK506 12.5mg</td>
<td>Flu/BU</td>
<td>erythema</td>
<td>arm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/M</td>
<td>57</td>
<td>MF</td>
<td>UR-BM</td>
<td>27</td>
<td>CsA 3mg/kg~., iv</td>
<td>Flu/BU</td>
<td>erythema</td>
<td>leg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>63</td>
<td>NHL</td>
<td>UR-BM</td>
<td>54</td>
<td>CsA 3mg/kg~., iv</td>
<td>Flu/BU</td>
<td>erythema, bulla</td>
<td>palm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F/M</td>
<td>35</td>
<td>ALL</td>
<td>UR-BM</td>
<td>14</td>
<td>FK506 12.5mg</td>
<td>CY/TBI</td>
<td>erythema</td>
<td>abdomen</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F/F</td>
<td>20</td>
<td>AML</td>
<td>UR-BM</td>
<td>20</td>
<td>FK506 12mg</td>
<td>CY/TBI</td>
<td>erythema, papule</td>
<td>palm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M/F</td>
<td>36</td>
<td>CML</td>
<td>R-PBSC</td>
<td>30</td>
<td>CSA 3mg/kg~., iv</td>
<td>CY/TBI</td>
<td>papule</td>
<td>palm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Supplemental Table 2. Patient profile (skin sampling)